New Trial Results: Kiora's KIO-301 Demonstrates Meaningful Vision Improvements in Retinitis Pigmentosa

Corporate Governance

To fulfill its fiduciary responsibilities, the Board of Directors of Kiora Pharmaceuticals (the “Company”) follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification as deemed appropriate by the Board of Directors in the best interests of the Company and its shareholders, or as required by applicable laws and regulations.

Loading RSS Feed